New Once-Daily Advagraf Launched Across Europe - New Formulation Provides A More Convenient Dosing Option For Organ Transplant Recipients
The EU-wide availability of the immunosuppressant Advagraf® (tacrolimus, prolonged release) is likely to bring greater convenience to patients who have had an organ transplant, announced Astellas at the 13th Congress of the European Society for Organ Transplantation in Prague. As the first calcineurin inhibitor (CNI) with a once-daily dosing option, Advagraf® has the potential to help improve clinical outcomes by improving adherence.
